Atara Biotherapeutics Inc
Change company Symbol lookup
Select an option...
ATRA Atara Biotherapeutics Inc
GATX GATX Corp
UAL United Airlines Holdings Inc
TEL TE Connectivity Ltd
HPGN HypGen Inc
IX Orix Corp
WHR Whirlpool Corp
PG Procter & Gamble Co
PWJAX PGIM Jennison International Opportunities Fund- Class A
MBWM Mercantile Bank Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Price
Delayed
$13.30
Day's Change
0.01 (0.08%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.39
Day's Low
12.84
Volume
(Light)

Today's volume of 37,408 shares is on pace to be much lighter than ATRA's 10-day average volume of 927,839 shares.

37,408

Scott+Scott Attorneys at Law LLP Investigates Microsoft Corp.'s Directors and Officers for Breach of Fiduciary Duties - MSFT

9:53 am ET April 7, 2021 (BusinessWire) Print

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Microsoft Corp. ("Microsoft") (NASDAQ: MSFT) breached their fiduciary duties to Microsoft and its shareholders. If you are a Microsoft shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether Microsoft's board of directors or senior management failed to manage Microsoft in an acceptable manner, in breach of their fiduciary duties to Microsoft, and whether Microsoft has suffered damages as a result.

On December 17, 2020, Reuters reported that Microsoft's cybersecurity systems were compromised. Evidence points to Russian intelligence agencies. On March 5, 2021, it was reported that newly discovered flaws in Microsoft Exchange Server software had been exploited to hack at least 30,000 organizations in the U.S.

What You Can Do

If you are a Microsoft shareholder, you may have legal claims against Microsoft's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005662/en/

SOURCE: Scott+Scott Attorneys at Law LLP

Joe Pettigrew 
Scott+Scott Attorneys at Law LLP 
230 Park Avenue, 17th Floor, New York, NY 10169 
844-818-6982 
jpettigrew@scott-scott.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.